Sunil V. Badve

Sunil V. Badve

Auto-generated profile, based on publicly available information

Sunil V. Badve

The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2020 in New England Journal of Medicine
Verified
Journal Article
Closed access
SBSunil V Badve
Sunil V Badve
EPElaine M Pascoe
Elaine M Pascoe
ATAnushree Tiku
Anushree Tiku
NBNeil Boudville
Neil Boudville
FBFiona G Brown
Fiona G Brown
CICKD-FIX Study Investigators
CKD-FIX Study Investigators
Elevated serum urate levels are associated with progression of chronic kidney disease. Whether urate-lowering treatment with allopurinol can attenuate the decline of the estimated glomerular filtration rate (eGFR) in patients with chronic kidney disease who are at risk for progression is not known.

19 July 2016 in JAMA
Verified
Journal Article
Closed access
PDF file
SPSuetonia C. Palmer
Suetonia C. Palmer
DMDimitris Mavridis
Dimitris Mavridis
ANAntonio Nicolucci
Antonio Nicolucci
DJDavid W. Johnson
David W. Johnson
MTMarcello Tonelli
Marcello Tonelli
GSGiovanni F. M. Strippoli
Giovanni F. M. Strippoli
Research from JAMA — Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes — A Meta-analysis

25 November 2024 in The Lancet Diabetes & Endocrinology
Verified
Journal Article
Closed access
SBSunil V Badve
Sunil V Badve
ABAnika Bilal
Anika Bilal
MLMatthew M Y Lee
Matthew M Y Lee
NSNaveed Sattar
Naveed Sattar
HGHertzel C Gerstein
Hertzel C Gerstein
VPVlado Perkovic
Vlado Perkovic

1 August 2012 in Journal of the American Society of Nephrology
Verified
Journal Article
Open access
PDF file
NBNeil Boudville
Neil Boudville
AKAnna Kemp
Anna Kemp
PCPhilip Clayton
Philip Clayton
WLWai Lim
Wai Lim
SBSunil V. Badve
Sunil V. Badve
DJDavid Johnson
David Johnson
Peritonitis is a major complication of peritoneal dialysis, but the relationship between peritonitis and mortality among these patients is not well understood. In this case-crossover study, we included the 1316 patients who received peritoneal dialysis in Australia and New Zealand from May 2004 through December 2009 and either died on peritoneal dialysis or within 30 days of transfer to hemodialysis. Each patient served as his or her own control. The mean age was 70 years, and the mean time receiving peritoneal dialysis was 3 years. In total, there were 1446 reported episodes of peritonitis with 27% of patients having ≥2 episodes. Compared with the rest of the year, there were significantly increased odds of peritonitis during the 120 days before death, although the magnitude of this association was much greater during the 30 days before death. Compared with a 30-day window 6 months before death, the odds for peritonitis was six-fold higher during the 30 days immediately before death (odds ratio, 6.2; 95% confidence interval, 4.4–8.7). In conclusion, peritonitis significantly associates with mortality in peritoneal dialysis patients. The increased odds extend up to 120 days after an episode of peritonitis but the magnitude is greater during the initial 30 days.

15 September 2013 in Nephrology Dialysis Transplantation
Verified
Journal Article
Closed access
BBBhadran Bose
Bhadran Bose
SBSunil V. Badve
Sunil V. Badve
SHSwapnil Hiremath
Swapnil Hiremath
NBNeil Boudville
Neil Boudville
FBFiona G. Brown
Fiona G. Brown
DJDavid W. Johnson
David W. Johnson
Non-randomized studies suggest an association between serum uric acid levels and progression of chronic kidney disease (CKD). The aim of this systematic review is to summarize evidence from randomized controlled trials (RCTs) concerning the benefits and risks of uric acid-lowering therapy on renal outcomes. Medline, Excerpta Medical Database and Cochrane Central Register of Controlled Trials were searched with English language restriction for RCTs comparing the effect of uric acid-lowering therapy with placebo/no treatment on renal outcomes. Treatment effects were summarized using random-effects meta-analysis. Eight trials (476 participants) evaluating allopurinol treatment were eligible for inclusion. There was substantial heterogeneity in baseline kidney function, cause of CKD and duration of follow-up across these studies. In five trials, there was no significant difference in change in glomerular filtration rate from baseline between the allopurinol and control arms [mean difference (MD) 3.1 mL/min/1.73 m2, 95% confidence intervals (CI) -0.9, 7.1; heterogeneity χ2=1.9, I2=0%, P=0.75]. In three trials, allopurinol treatment abrogated increases in serum creatinine from baseline (MD -0.4 mg/dL, 95% CI -0.8, -0.0 mg/dL; heterogeneity χ2=3, I2=34%, P=0.22). Allopurinol had no effect on proteinuria and blood pressure. Data for effects of allopurinol therapy on progression to end-stage kidney disease and death were scant. Allopurinol had uncertain effects on the risks of adverse events. Uric acid-lowering therapy with allopurinol may retard the progression of CKD. However, adequately powered randomized trials are required to evaluate the benefits and risks of uric acid-lowering therapy in CKD.

26 November 2024 in Circulation
Verified
Journal Article
Closed access
BNBrendon L. Neuen
Brendon L. Neuen
RFRobert A. Fletcher
Robert A. Fletcher
LHLauren Heath
Lauren Heath
APAdam Perkovic
Adam Perkovic
MVMuthiah Vaduganathan
Muthiah Vaduganathan
HHHiddo Heerspink
Hiddo Heerspink
BACKGROUND: GLP-1 (glucagon-like peptide-1) receptor agonists and SGLT2 (sodium-glucose cotransporter 2) inhibitors both improve cardiovascular and kidney outcomes in people with type 2 diabetes. We conducted a systematic review and meta-analysis to assess the effects of GLP-1 receptor agonists on clinical outcomes with and without SGLT2 inhibitors. METHODS: We searched MEDLINE and Embase databases from inception until July 12, 2024, for randomized, double-blind, placebo-controlled outcome trials of GLP-1 receptor agonists in type 2 diabetes that reported treatment effects by baseline use of SGLT2 inhibitors, with findings supplemented by unpublished data. We estimated treatment effects by baseline SGLT2 inhibitor use using inverse variance-weighted meta-analysis. The main cardiovascular outcomes were major adverse cardiovascular events (nonfatal myocardial infarction, stroke, or cardiovascular death) and hospitalization for heart failure. Kidney outcomes included a composite of ≥50% reduction in estimated glomerular filtration rate, kidney failure or death caused by kidney failure, and annualized rate of decline in estimated glomerular filtration rate (estimated glomerular filtration rate slope). Serious adverse events and severe hypoglycemia were also evaluated. This meta-analysis was registered on the International Prospective Register of Systematic Reviews (PROSPERO; CRD42024565765). RESULTS: We identified 3 trials with 1743 of 17 072 (10.2%) participants with type 2 diabetes receiving an SGLT2 inhibitor at baseline. GLP-1 receptor agonists reduced the risk of major adverse cardiovascular events by 21% (hazard ratio [HR], 0.79 [95% CI, 0.71–0.87]), with consistent effects in those receiving and not receiving SGLT2 inhibitors at baseline (HR, 0.77 [95% CI, 0.54–1.09] and HR, 0.79 [95% CI, 0.71–0.87], respectively; P -heterogeneity=0.78). The effect on hospitalization for heart failure was similarly consistent regardless of SGLT2 inhibitor use (HR, 0.58 [95% CI, 0.36–0.93] and HR, 0.73 [95% CI, 0.63–0.85]; P -heterogeneity=0.26). Effects on the composite kidney outcome (risk ratio, 0.79 [95% CI, 0.66–0.95]) and estimated glomerular filtration rate slope (0.78 mL/min/1.73 m 2 /y [95% CI, 0.57–0.98]) also did not vary according to SGLT2 inhibitor use ( P -heterogeneity=0.53 and 0.94, respectively). Serious adverse effects and severe hypoglycemia were also similar regardless of SGLT2 inhibitor use ( P -heterogeneity=0.29 and 0.50, respectively). CONCLUSIONS: In people with type 2 diabetes, the cardiovascular and kidney benefits of GLP-1 receptor agonists are consistent regardless of SGLT2 inhibitor use.